• NEWS . 08 Jun 2020
  • Ticagrelor linked to low bleeding and CV events in NSTEMI patients

  • In a phase IV, single-arm study of Taiwanese patients with non ST-segment elevation myocardial infarction (NSTEMI), ticagrelor for up to 1 year was associated with a low rate of major bleeding events and a low incidence of major cardiovascular (CV) events. 

    In the study, the safety of ticagrelor was evaluated according to adverse events (AEs), serious AEs (SAEs) and PLATO-defined bleeding events, as well the cumulative incidence of major CV events (CV death, myocardial infarction and stroke). 

    Of the 108 patients included across 13 centres, 32 (29.6%) had ≥1 PLATO-defined bleeding event. Seven (6.5%) patients experienced major bleeding events with a Kaplan–Meier (KM) estimated event risk of 7.1% (95% confidence interval [CI], 3.4–14.4). Of these, four (3.7%) had life-threatening bleeding and three (2.8%) had other major bleeding. No PLATO-defined fatal bleeding was observed. SAEs were reported in 23 (21.3%) patients, whereas six (5.6%) patients had major CV events during the 1-year follow-up period (KM-estimated event risk 5.6%; 95% Cl, 2.6–12.0).

    The researchers also added that the overall safety of ticagrelor was consistent with its established safety profile. 

    Reference: 
    Mar GY, et al. Safety and cumulative incidence of major cardiovascular events with ticagrelor in Taiwanese patients with non-ST-segment elevation myocardial infarction: A 12-month, prospective, phase IV, multicenter, single-arm study. Acta Cardiol Sin 2020;36:195–206.